Antidepressant Treatment of AIDS Related Depression. - Full Text View

Sponsored by:	GEIGY Pharmaceuticals
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00000390

Purpose

To test the effectiveness treating AIDS related depression with imipramine hydrochloride.

Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.

This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Condition	Intervention	Phase
Depression	Drug: Imipramine hydrochloride	Phase II

Study Type:	Interventional
Study Design:	Treatment, Placebo Control

Resource links provided by NLM:

MedlinePlus related topics: AIDS Antidepressants Depression

Drug Information available for: Imipramine Imipramine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Detailed Description:

To test the effectiveness treating AIDS related depression with imipramine hydrochloride.

Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.

This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented.
May have been alcoholic or drug abuser 6 months previous.
Unspecified
CD4 Unspecified.

Exclusion Criteria:

Non ambulatory patients or those requiring extensive help in self care are excluded.
Non ambulatory patients or those requiring extensive help in self care are excluded.
Current alcohol or drug abuse.
Unspecified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000390

Locations

United States, New York
New York Hosp - Cornell Med Ctr
New York, New York, United States, 10021

Sponsors and Collaborators

GEIGY Pharmaceuticals

Investigators

Study Chair:	Frances A
Study Chair:	Manning D

More Information

No publications provided

Study ID Numbers:	87-DEP
Study First Received:	January 17, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000390 History of Changes
Health Authority:	Unspecified

Keywords provided by National Institute of Mental Health (NIMH):

Adult
Acquired Immunodeficiency Syndrome
Depression
Female
Human
Imipramine

Male
Middle Age
Acquired Immunodeficiency Syndrome -- *complications
Depression -- *drug therapy
Depression -- etiology
Imipramine -- *therapeutic use

Study placed in the following topic categories:

Neurotransmitter Agents
Depression
Adrenergic Agents
Acquired Immunodeficiency Syndrome
Psychotropic Drugs
Depressive Disorder
Immunologic Deficiency Syndromes

Behavioral Symptoms
Antidepressive Agents, Tricyclic
Imipramine
HIV Infections
Mental Disorders
Mood Disorders
Antidepressive Agents

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Depression
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Depressive Disorder

Pharmacologic Actions
Behavioral Symptoms
Antidepressive Agents, Tricyclic
Imipramine
Mental Disorders
Therapeutic Uses
Mood Disorders
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on July 02, 2009